Skip to main content

Novel Rx

Review of Emerging Treatments for Vitiligo an immune mediated dz that affects QOL & has psychosocial impact. JAKi only ruxolitinib is FDA-approved, but Tofa & Bari show promise. Emerging therapies include simvastatin, afamelanotide, and metformin https://t.co/Rp2yYx6SyZ https://t.co/pBo1IDe8pQ
Dr. John Cush @RheumNow( View Tweet )
Systematic review of JAK inhibitor use in systemic sclerosis - 18 articles/87 SSc pts (80%F; ages 13–78 yrs). JAKi (83% tofa) mostly used for ILD & Skin Dz (45%) or GI+Skin Dz (39%). 87.5% improved, w/ 6% relapsed. Adverse events in 50% (20% infx). We need RCTs! This could be a https://t.co/VXFuHGpDjB
Dr. John Cush @RheumNow( View Tweet )
SLE Treatment Landscape: Abundance or Overload? Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we https://t.co/1SsSMqfZWz
Dr. John Cush @RheumNow( View Tweet )

Methotrexate Fails in Knee Osteoarthritis

MedPage Today

We'll be blunt: methotrexate flopped in a randomized placebo-controlled trial among patients with osteoarthritis (OA) of the knee.

Contrary to results from a previous trial in hand OA, the old-line disease-modifying anti-rheumatic drug (DMARD) failed to bring any improvement relative to placebo

Read Article
Do SGLT2 and GLP-1 therapies have a role in Lupus? Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/8JEfcv2BUz
Dr. John Cush @RheumNow( View Tweet )
A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab https://t.co/jqDmKinPDt
Dr. John Cush @RheumNow( View Tweet )
Using publicly available FAERS safety data, drug-induced photosensitivity (DIP) - among 17+ million safety reports, there 20,236 linked to DIP. The most common wereimmunosuppressants, monoclonal Abs, neoplastic agents, including adalimumab, adapalene, secukinumab, fingolimod https://t.co/QWg8FVvrZb
Dr. John Cush @RheumNow( View Tweet )

SLE Treatment Landscape: Abundance or Overload?

Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we may have true difficulty choosing what to use.

Read Article

Do SGLT2 and GLP-1 therapies have a role in Lupus?

Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA) were initially developed as glucose-lowering agents for the treatment of Type 2 Diabetes. Since their introduction, they have been noted to have a myriad of other benefits, including

Read Article

Belimumab in SLE with Mucocutaneous or Vasculitis Findings

A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.

Read Article

50 Year Perspective on Lupus

An observational cohort study was started in Toronto by Dr. Murray Urowitz in 1970. The program was set up as a specialized clinic to provide care for patients with lupus, to study clinical laboratory correlations in the disease, and to better understand long-term outcomes of the disease. What

Read Article
A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab https://t.co/fBdfrrZt1M
Dr. John Cush @RheumNow( View Tweet )

2025 ACR Guideline for the Treatment of SLE

The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. 

Overall, the goals of SLE management are to achieve remission or a low level disease activity, reduce

Read Article
IL2 low dose in #SLE seems to + alter immune regulation Multiple targets to explore in #lupus Unravelling pathophysiology in SLE CD40L TLR7,8 #rapamycin type drugs CAR-T w novel CARS Etc #LUPUS2025 @RheumNow https://t.co/jeycgg4ZhT
Janet Pope @Janetbirdope( View Tweet )
>200 genes 🧬 implicated in #SLE Complex indeed! And ▶️ 7 clusters of signalling pathways So we have to have many Rx options Ab patterns vary LN flares can have v diff pathways between Pts #LUPUS2025 @RheumNow Unravelling #LUPUS2026 https://t.co/LEKN363194
Janet Pope @Janetbirdope( View Tweet )

Diagnosing Neuropsychiatric SLE (5.23.2025)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

Read Article
Systematic review and meta-analysis confirms modest efficacy of infliximab for pulmonary sarcoidosis and promising but limited evidence for adalimumab, tofacitinib and efzofitimob in specific sarcoid manifestations. https://t.co/XaqSiAVQTa https://t.co/DTGbIiPT3a
Dr. John Cush @RheumNow( View Tweet )

Shifting the Management Paradigm for SLE and Lupus Nephritis

The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.

Read Article
Emerging therapies targeting the NLRP3-inflammasome (active in Autoinflammatory Dz, Gout, neurodegenerative Dz/Alzheimers). Currently no FDA approved drugs, but many in trials. eg, Oxidized DNA (DAMP) activates NLRP3 & may be blocked by repurposed glycosylase inhibitors to reduce https://t.co/CJv50LVKhy
Dr. John Cush @RheumNow( View Tweet )
CAR-T and cellular depletion therapies gone wild! Currently there are over 85 different therapeutic candidates aiming to reset the immune system in >380 clinical trials. Review article looks at indications, targets, modalities & outlook. https://t.co/yleR4B48IY https://t.co/WwSPzIPomk
Dr. John Cush @RheumNow( View Tweet )

Moving Targets in Lupus and Lupus Trials

Clinical trial data quality is a moving target. Lupus is also a moving target. Can we address the moving target of lupus pathology with the moving targets of quality clinical trials and scientific treatment selection?

Read Article

Biologics in Pregnancy Patients With Autoimmune Disease

A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients than those with rheumatoid arthritis (RA), psoriasis (PsO) or psoriatic

Read Article
Deep remission in SLE – what is it, and can we achieve it? Recent reports on lupus patients treated with CAR-T cells targeting CD19+ B lymphocytes have sparked excitement. This is due to the patients experiencing ongoing clinical remission without further treatment after two https://t.co/rdBkIhfWWd
Dr. John Cush @RheumNow( View Tweet )

Panacea of Prednisone & Cannabis (5.16.2025)

Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com.  Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too!

Read Article
FDA approved the chikungunya virus vaccine (Ixchiq) in 11/23, but recently announced caution and pause use while it investigates Postmarketing Safety Reports of 17 SAE (cardiac & neurologic) & 2 deaths. 6 SAE in the USA, elderly w/ chronic med conditions. ~80K doses of Ixchiq https://t.co/XadqMEmSuD
Dr. John Cush @RheumNow( View Tweet )
×